FOLD
Price
$9.54
Change
+$0.03 (+0.32%)
Updated
Jan 22 closing price
Capitalization
2.85B
34 days until earnings call
MRNS
Price
$0.54
Change
-$0.00 (-0.00%)
Updated
Jan 22, 04:59 PM (EDT)
Capitalization
30.09M
47 days until earnings call
Ad is loading...

FOLD vs MRNS

Header iconFOLD vs MRNS Comparison
Open Charts FOLD vs MRNSBanner chart's image
Amicus Therapeutics
Price$9.54
Change+$0.03 (+0.32%)
Volume$1.64M
Capitalization2.85B
Marinus Pharmaceuticals
Price$0.54
Change-$0.00 (-0.00%)
Volume$13.1K
Capitalization30.09M
FOLD vs MRNS Comparison Chart
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. MRNS commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Hold and MRNS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (FOLD: $9.54 vs. MRNS: $0.55)
Brand notoriety: FOLD and MRNS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 68% vs. MRNS: 110%
Market capitalization -- FOLD: $2.85B vs. MRNS: $30.09M
FOLD [@Biotechnology] is valued at $2.85B. MRNS’s [@Biotechnology] market capitalization is $30.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileMRNS’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • MRNS’s FA Score: 0 green, 5 red.
According to our system of comparison, MRNS is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 2 TA indicator(s) are bullish while MRNS’s TA Score has 4 bullish TA indicator(s).

  • FOLD’s TA Score: 2 bullish, 3 bearish.
  • MRNS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both FOLD and MRNS are a bad buy in the short-term.

Price Growth

FOLD (@Biotechnology) experienced а +2.91% price change this week, while MRNS (@Biotechnology) price change was +0.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.70%. For the same industry, the average monthly price growth was +2.32%, and the average quarterly price growth was -2.48%.

Reported Earning Dates

FOLD is expected to report earnings on May 07, 2025.

MRNS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+1.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($2.85B) has a higher market cap than MRNS($30.1M). MRNS YTD gains are higher at: 1.850 vs. FOLD (1.274). FOLD has higher annual earnings (EBITDA): -9.2M vs. MRNS (-122.86M). FOLD has more cash in the bank: 250M vs. MRNS (42.2M). MRNS has less debt than FOLD: MRNS (56M) vs FOLD (445M). FOLD has higher revenues than MRNS: FOLD (494M) vs MRNS (31.5M).
FOLDMRNSFOLD / MRNS
Capitalization2.85B30.1M9,472%
EBITDA-9.2M-122.86M7%
Gain YTD1.2741.85069%
P/E RatioN/AN/A-
Revenue494M31.5M1,568%
Total Cash250M42.2M592%
Total Debt445M56M795%
FUNDAMENTALS RATINGS
FOLD vs MRNS: Fundamental Ratings
FOLD
MRNS
OUTLOOK RATING
1..100
2230
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
7940
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a32

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRNS's Valuation (50) in the Pharmaceuticals Other industry is in the same range as FOLD (76) in the Biotechnology industry. This means that MRNS’s stock grew similarly to FOLD’s over the last 12 months.

MRNS's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as FOLD (100) in the Biotechnology industry. This means that MRNS’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's SMR Rating (98) in the Biotechnology industry is in the same range as MRNS (100) in the Pharmaceuticals Other industry. This means that FOLD’s stock grew similarly to MRNS’s over the last 12 months.

MRNS's Price Growth Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for FOLD (79) in the Biotechnology industry. This means that MRNS’s stock grew somewhat faster than FOLD’s over the last 12 months.

MRNS's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as FOLD (100) in the Biotechnology industry. This means that MRNS’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDMRNS
RSI
ODDS (%)
N/A
Bearish Trend 16 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 16 days ago
72%
Bearish Trend 16 days ago
86%
Momentum
ODDS (%)
Bearish Trend 16 days ago
83%
Bullish Trend 16 days ago
81%
MACD
ODDS (%)
Bearish Trend 16 days ago
83%
N/A
TrendWeek
ODDS (%)
Bullish Trend 16 days ago
73%
Bearish Trend 16 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 16 days ago
75%
Bullish Trend 16 days ago
81%
Advances
ODDS (%)
Bullish Trend 16 days ago
73%
Bullish Trend 24 days ago
82%
Declines
ODDS (%)
Bearish Trend 25 days ago
75%
Bearish Trend 16 days ago
81%
BollingerBands
ODDS (%)
N/A
Bearish Trend 16 days ago
84%
Aroon
ODDS (%)
N/A
Bearish Trend 16 days ago
77%
View a ticker or compare two or three
Ad is loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LZUSX17.140.09
+0.53%
Lazard US Equity Focus Instl
GQIRX48.59N/A
N/A
Goldman Sachs US Tax-Managed Eq Inv
DVFYX70.10-0.03
-0.04%
Davis Financial Y
AFMFX56.91-0.05
-0.09%
American Funds American Mutual F3
PHRAX18.78-0.33
-1.73%
Virtus Duff & Phelps Real Estate Secs A

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with ALDX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+0.32%
ALDX - FOLD
44%
Loosely correlated
+2.86%
VCYT - FOLD
43%
Loosely correlated
-1.26%
SRPT - FOLD
42%
Loosely correlated
-0.60%
DNLI - FOLD
40%
Loosely correlated
+1.17%
XERS - FOLD
39%
Loosely correlated
-1.50%
More

MRNS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNS has been loosely correlated with AXON. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNS
1D Price
Change %
MRNS100%
+0.55%
AXON - MRNS
40%
Loosely correlated
+0.33%
NTLA - MRNS
37%
Loosely correlated
+10.76%
FOLD - MRNS
36%
Loosely correlated
+0.32%
AMRN - MRNS
35%
Loosely correlated
-4.00%
SAGE - MRNS
33%
Poorly correlated
+1.01%
More